Splitomicin is a small-molecule inhibitor that binds to the protein SIRT2 and inhibits its NAD+-dependent HDAC activity. HDAC inhibitors focus on HDAC enzymes, hindering the growth of cancer cells and triggering apoptosis, the programmed death of cancer cells. Reagent-grade; for laboratory research purposes only.
Usually ships within 24 hours.